In vitro antifungal activity of polyfunctionalized 2-(hetero)arylquinolines prepared through imino Diels–Alder reactions
摘要:
Diverse polyfunctionalized quinolines, easily prepared using Lewis acid-catalyzed imino Diels-Alder reactions between corresponding aldimines, were tested for antifungal properties against standardized as well as clinical isolates of clinically important fungi. Among them, 4-pyridyl derivatives displayed the best activities mainly against dermatophytes. The activity appears not to be related neither to the lipophilicity nor to the basicity of compounds. (C) 2008 Elsevier Ltd. All rights reserved.
Phosphotungstic Acid: An Efficient Catalyst for Synthesis of 2-Substituted Tetrahydroquinoline via Imino Diels–Alder Reaction and Fluorescent Studies
摘要:
For the first time Phosphotungstic acid (PTA), is used as a some new catalyst for the synthesis of tetrahydroquinoline derivatives with high yields is described. PTA a heterogeneous catalyst is inexpensive, easily available, eco-friendly, water soluble, recoverable, stable to aqueous reaction conditions and further more, these 2-methyl tetrahydroquinoline derivatives shows a remarkable fluorescence property.
An efficient one-pot synthesis of tetrahydroquinoline derivatives via an aza Diels–Alder reaction mediated by CAN in an aqueous medium and oxidation to heteroaryl quinolines
作者:G. Savitha、P.T. Perumal
DOI:10.1016/j.tetlet.2006.03.046
日期:2006.5
Various tetrahydroquinoline derivatives have been synthesized by employing ceric ammonium nitrate in an aqueous medium. Subsequently, the tetrahydroquinolines were oxidized to biheterocycles. (c) 2006 Elsevier Ltd. All rights reserved.
[EN] EG5 AS BIOMARKER IN RARE THORACIC CANCER<br/>[FR] UTILISATION DE L’EG5 COMME BIOMARQUEUR DANS LES TUMEURS THORACIQUES RARES
申请人:MERCK PATENT GMBH
公开号:WO2011009523A1
公开(公告)日:2011-01-27
The invention relates to an in-vitro method for predicting the likelihood that a patient suffering from a thoracic tumor will respond to the treatment with an Eg5 inhibitory compound by determining the expression level of the eg5 gene or Eg5 protein as biomarker in a tissue sample from the patient, wherein a higher expression level of the eg5 gene or Eg5 protein indicates that the patient is likely to respond to the treatment compared to a reference value. Another object of the invention concerns a method for monitoring a thoracic tumor, which is associated with Eg5 expression, by administering an effective amount of at least a single Eg5 inhibitor to a mammal in need of such treatment and determining the Eg5 expression in a biological sample withdrawn from the mammal, and wherein a decrease in Eg5 expression indicates an increased likelihood that the mammal responds to the treatment with the inhibitor. The invention also relates to the use of Eg5 as biomarker for rare thoracic tumors.